Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 87-94

  Dieterich, Douglas T ^a   Purow, Joshua M ^b   Rajapaksa, Roshini ^b  

^a Liberty Medical LLP   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus; Human immunodeficiency virus; Interferon alpha; Ribavirin

Indexed keywords

REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

DISEASE COURSE; DRUG SAFETY; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER HISTOLOGY; MALAISE; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0032953101     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Merrick ST, Sepkowitz KA, Boyle BA, Jacobs JL. Seroprevalence of hepatitis C antibody and hepatitis B surface antigenemia in a large urban HIV clinic [abstract]. In: Program and Abstracts of the 12th World AIDS Conference (Geneva). Geneva, Switzerland: 1998:315. Abstract 22263
2. McNair AN, Main J, Thomas HC. Interactions of the human immunodeficiency virus and the hepatotropic viruses. Semin Liver Dis 1992;12:188-196
3. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of co-infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993;6:602-610
4. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690
5. Zylberberg H, Pol S. Reciprocal interaction between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-1125
6. Collier J, Heathcote J. Hepatitis C viral infection in the immuno-suppressed patient. Hepatology 1998;27:2-6
7. Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. Genitourin Med 1996;72:213-216
8. Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997;35:163-166
9. Marcellin P, Colin JF, Martinot-Peignoux M, et al. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second-and third-generation anti-HCV testing. Liver 1993; 13:319-322
10. Hallam NF, Fletcher ML, Read SJ, Majid AM, Kurtz JB, Rizza CR. Low risk of sexual transmission of hepatitis C virus. J Med Virol 1993;40:251-253
11. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood 1992;80:540-543
12. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings. J Intern Med 1994; 236:515-519
13. Sawanpanyalert P, Boonmar S, Maeda T, Matsuura Y, Miyamura T. Risk factors for hepatitis C virus infection among blood donors in an HIV-epidemic area in Thailand. J Epidemiol Community Health 1996;50:174-177
14. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991;115:764-768
15. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-1488
16. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-695
17. Cribier B, Rey D, Schmitt C, Lang JM, Kim A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-1136
18. Marcellin P, Boyer N, Pouteau M, Benhamou JP, Erlinger S. Retreatment with interferon-alpha of chronic hepatitis C virus infection [letter; comment]. Lancet 1994;344:690-691
19. Lefrere JJ, Guiramand S, Lefrere F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997;175:316-322
20. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-166
21. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974
22. Pol S, Rothschild C, Poussin K, et al. HIV co-infection does not modify HCV infection profile in hemophiliacs [abstract]. J Hepatol 1994;21:122. Abstract 111
23. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023
24. Cribier B, Schmitt C, Rey D, et al. HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 1997;148:267-271
25. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997;92:1130-1134
26. Guido M, Rugge M, Fattovich G, et al. Human immunodeficiency virus infection and hepatitis C pathology. Liver 1994;14:314-319
27. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997;430:271-277
28. Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994;170:1018-1022
29. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-953
30. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5
31. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JL. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989;97:1559-1561
32. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290
33. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-886
34. Berenguer M, Wright TL. Are HCV-infected individuals candidates for hepatitis A vaccine? Lancet 1998;351:924-925
35. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-388
36. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997;175:164-168
37. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994;20:1152-1155
38. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587
39. Quan CM, Krajden M, Grigoricw GA, Salitt IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993;17:117-119
40. Poles MA, Lew EA, Dieterich DT. Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterol Clin North Am 1997;26:291-321
41. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23:8-12
42. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-706
43. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-618
44. McHutchison JG, Gordon SC, Eugene R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
45. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432
46. Dieterich DT. The new importance of liver disease in HIV. The Physician's Research Network Notebook 1998;3:13-16
47. Aguilar Y, Ryocc R, Antunez JM, Jimenez OR, Trujillo F. Interferon treatment of chronic hepatitis C infection in HIV infected and high risk uninfected people in Malaga Spain [abstract]. In: Program and Abstracts of the 8th International Conference on AIDS (Amsterdam). Amsterdam, The Netherlands: CONGREX Holland BV; 1992:B163. Abstract 3478
48. Del Pozo MA, Arias JR, Garroto E, et al. A long term multicentric trial of recombinant interferon alpha 2b and zidovudine in HIV infected patients with chronic hepatitis C: response related factors [abstract]. Hepatology 1994:21:170A. Abstract 296
49. Garcia-Samaniengo J, Soriano V, Bravo R, et al. Efficacy and safety of alpha interferon therapy for chronic hepatitis C in HIV patients [abstract]. Hepatology 1994;20:162A. Abstract 263
50. Linares C, Sorda JA, Findor JA. Efficacy of recombinant IFN alpha in chronic hepatitis C of HIV positive patients [abstract]. J Hepatol 1994;21:113. Abstract 76
51. Soriano V. Garcia-Samaniego JBR, et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. J Infection 1995;31:9-13
52. Spanish Group for Treatment of Hepatitis in HIV-Positive Patients. Interferon therapy for chronic hepatitis C in HIV+ infected patients [abstract]. In: Program and Abstracts of the 9th International Conference on AIDS (Berlin). Berlin, Germany: Institute for Clinical and Experimental Virology of the Free University of Berlin; 1993:D08. Abstract 1310
53. Arcias J, Pedroto I, Barrias S, Maros P, Freitas T, Saraiva AM. Pilot study of interferon alpha 2b treatment of chronic hepatitis C in patients coinfected with the human immunodeficiency virus [abstract]. Hepatology 1994;20:162A. Abstract 264
54. Boyer N, Marcellin P, Degon C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992;165: 723-726
55. De Sanctis GM, Errera G, Barbacini IG, Bergami N, Chireu LV. Long term outcome of chronic hepatitis infection in HIV + subject treated with interferon [abstract]. In: Program and Abstracts of the 9th International Conference on AIDS (Berlin). Berlin, Germany: Institute for Clinical and Experimental Virology of the Free University of Berlin; 1993:B19. Abstract 1822
56. Marcellin P, Boyer N, Arejas J, Erlinger S, Benhamou JP. Comparison of efficacy of alpha interferon in former intravenous drug addicts with chronic hepatitis C with or without HIV infection [abstract). Gastroenterology 1994;106:A938. Abstract 938
57. Marriott E, Navas S, del Romero J, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993;40:10)7-111
58. Nardiello S, Garginlo M, Pizella T, et al. Interferon treatment for chronic HCV and NANB hepatitis in HIV seropositive patients [abstract]. In: Program and Abstracts of the 8th International Conference on AIDS (Amsterdam). Amsterdam, The Netherlands: CONGREX Holland BV; 1992:6149. Abstract 3373
59. Pol S, Trinh T, Thiers V, et al. Chronic hepatitis of drug users: influence of HIV infection [abstract]. Hepatology 1995;22:340A. Abstract 933
60. Weisz K, Dreiswirth S, McMeeking M, et al. Erythropoietin use for ribavirin/interferon induced anemia in patients with hepatitis C [abstract). Hepatology 1998;28:288A. Abstract 501
61. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379
62. Japour AJ, Lertora JJ, Meehan PM, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:235-246
63. Bernier R, Tremblay M, Tsoukas C, Bergeron MG. Drug sensitivity of human immunodeficiency virus type I isolates after ribavirin therapy. J Infect Dis 1997;175:176-178